CSE's recent assessment on the antibiotic development crisis shows that the pipeline of new antibiotics continues to be weak. Major pharmaceutical companies are opting out of research and development for new antibiotics not just because it is a high-risk and low-return proposition, but also because there is much more profit in drugs that are used for treating diseases like cancer or diabetes. Small and medium biopharmaceutical antibiotic developers are also facing big challenges. It is also clear that the current support provided is not enough and a lot needs to be done to stimulate the antibiotic R&D ecosystem for a sustainable and equitable antibiotic access. It is time to think about antibiotics as a ‘global public good’.